{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:38:40Z","timestamp":1761863920126,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Cancer Council South Australian"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clcc.2018.12.002","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T02:33:54Z","timestamp":1546482834000},"page":"141-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial"],"prefix":"10.1016","volume":"18","author":[{"given":"Gonzalo","family":"Tapia Rico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-2693","authenticated-orcid":false,"given":"Timothy","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niall","family":"Tebbutt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Hardingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Buizen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2018.12.002_bib1","first-page":"177","article-title":"Colorectal cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2018.12.002_bib2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2018.12.002_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Muzny","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.clcc.2018.12.002_bib4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.7326\/0003-4819-113-10-779","article-title":"Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location","volume":"113","author":"Bufill","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clcc.2018.12.002_bib5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/oxfordjournals.jmicro.a023433","article-title":"Comparison of mucosal microvasculature between the proximal and distal human colon","volume":"45","author":"Araki","year":"1996","journal-title":"J\u00a0Electron Microsc (Tokyo)"},{"key":"10.1016\/j.clcc.2018.12.002_bib6","first-page":"725","article-title":"Morphometrical and cell kinetic studies of normal human colorectal mucosa. Comparison between the proximal and the distal large intestine","volume":"39","author":"Arai","year":"1989","journal-title":"Acta Pathol Jpn"},{"key":"10.1016\/j.clcc.2018.12.002_bib7","first-page":"10","article-title":"[Two colons\u2014two cancers? Proximal or distal adenocarcinoma: arguments for a different carcinogenesis]","volume":"82","author":"Pocard","year":"1995","journal-title":"Bull Cancer"},{"key":"10.1016\/j.clcc.2018.12.002_bib8","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000171605","article-title":"Are right- and left-sided colon neoplasms distinct tumors?","volume":"15","author":"Distler","year":"1997","journal-title":"Dig Dis"},{"key":"10.1016\/j.clcc.2018.12.002_bib9","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.prp.2012.07.003","article-title":"Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma","volume":"208","author":"Benedix","year":"2012","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.clcc.2018.12.002_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2353\/jmoldx.2006.050052","article-title":"Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas","volume":"8","author":"Sugai","year":"2006","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.clcc.2018.12.002_bib11","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ejca.2015.03.015","article-title":"Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17","volume":"1","author":"Brul\u00e9","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2018.12.002_bib12","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1093\/annonc\/mdt253","article-title":"Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer","volume":"24","author":"Boisen","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.12.002_bib13","doi-asserted-by":"crossref","first-page":"dju427","DOI":"10.1093\/jnci\/dju427","article-title":"Primary tumor location as a prognostic factor in metastatic colorectal cancer","volume":"107","author":"Loupakis","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clcc.2018.12.002_bib14","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1200\/JCO.2009.27.7723","article-title":"Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX study","volume":"28","author":"Tebbutt","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.12.002_bib15","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2010.34.5520","article-title":"Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer","volume":"29","author":"Price","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.12.002_bib16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ijc.28698","article-title":"Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer","volume":"135","author":"Bruhn","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2018.12.002_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/cam4.75","article-title":"Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab","volume":"2","author":"Price","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.clcc.2018.12.002_bib18","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bjc.2015.37","article-title":"Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer","volume":"112","author":"Price","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2018.12.002_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/bjc.2015.209","article-title":"Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer","volume":"113","author":"Weickhardt","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2018.12.002_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejso.2010.12.004","article-title":"Colon carcinoma\u2014classification into right and left sided cancer or according to colonic subsite? Analysis of 29,568 patients","volume":"37","author":"Benedix","year":"2011","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.clcc.2018.12.002_bib21","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejso.2014.11.001","article-title":"Is right-sided colon cancer different to left-sided colorectal cancer? A systematic review","volume":"41","author":"Lee","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.clcc.2018.12.002_bib22","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1245\/s10434-008-0015-y","article-title":"Is there a difference in survival between right- versus left-sided colon cancers?","volume":"15","author":"Meguid","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clcc.2018.12.002_bib23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CAD.0000000000000041","article-title":"Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment)","volume":"25","author":"Modest","year":"2014","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clcc.2018.12.002_bib24","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1200\/JCO.2016.34.15_suppl.3504","article-title":"Impact of primary (1\u00b0) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB\/SWOG 80405 (Alliance)","volume":"34","author":"Venook","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.12.002_bib25","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0140-6736(10)60551-X","article-title":"Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial","volume":"375","author":"Atkin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2018.12.002_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.7326\/0003-4819-154-1-201101040-00004","article-title":"Protection from colorectal cancer after colonoscopy: a population-based, case\u2013control study","volume":"154","author":"Brenner","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clcc.2018.12.002_bib27","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","article-title":"Distal and proximal colon cancers differ in\u00a0terms of molecular, pathological, and clinical features","volume":"25","author":"Missiaglia","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.12.002_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000443644","article-title":"Right sided colon cancer as a distinct histopathological subtype with reduced prognosis","volume":"33","author":"Nitsche","year":"2016","journal-title":"Dig Surg"},{"key":"10.1016\/j.clcc.2018.12.002_bib29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/1471-2407-13-439","article-title":"Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer","volume":"13","author":"Popovici","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2018.12.002_bib30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/DCR.0b013e31821b9bf2","article-title":"Predictive factors for pulmonary metastases after curative resection of rectal cancer without preoperative chemoradiotherapy","volume":"54","author":"Watanabe","year":"2011","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.clcc.2018.12.002_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/1477-7819-12-197","article-title":"Rectal cancer level significantly affects rates and patterns of distant metastases among rectal cancer patients post curative-intent surgery without neoadjuvant therapy","volume":"12","author":"Chiang","year":"2014","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.clcc.2018.12.002_bib32","first-page":"e9","article-title":"Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer","volume":"15","author":"Wong","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2018.12.002_bib33","first-page":"3865","article-title":"VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival","volume":"28","author":"Bendardaf","year":"2008","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clcc.2018.12.002_bib34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2005.01.5388","article-title":"Impact of vascular endothelial growth factor\u2014a expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer","volume":"24","author":"Jubb","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.12.002_bib35","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1111\/j.1572-0241.2000.02327.x","article-title":"Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes\u2019 C colon cancer","volume":"95","author":"Bleeker","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clcc.2018.12.002_bib36","first-page":"1193","article-title":"Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study","volume":"9","author":"Samowitz","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clcc.2018.12.002_bib37","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/gutjnl-2011-300865","article-title":"Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum","volume":"61","author":"Yamauchi","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.clcc.2018.12.002_bib38","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1200\/JCO.2010.30.1366","article-title":"Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer","volume":"29","author":"Hutchins","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.12.002_bib39","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ejca.2015.03.015","article-title":"Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17","volume":"51","author":"Brule","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2018.12.002_bib40","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00432-014-1678-3","article-title":"Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12\/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial","volume":"140","author":"von Einem","year":"2014","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clcc.2018.12.002_bib41","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s40880-015-0022-x","article-title":"Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab","volume":"34","author":"Wang","year":"2015","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.clcc.2018.12.002_bib42","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1038\/bjc.2013.212","article-title":"The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer","volume":"108","author":"Eklof","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2018.12.002_bib43","first-page":"2345","article-title":"BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency anaemia","volume":"35","author":"Sideris","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clcc.2018.12.002_bib44","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.clcc.2018.12.002_bib45","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/annonc\/mdy410","article-title":"The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial","volume":"29","author":"Mooi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.12.002_bib46","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cncr.29129","article-title":"Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?","volume":"121","author":"Price","year":"2015","journal-title":"Cancer"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002818305188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002818305188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:06:39Z","timestamp":1761519999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002818305188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1533002818305188"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2018.12.002","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2018.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}